Inactivating TP53 mutations were detected in nearly half of cases; this finding is consistent with prior data suggesting that inactivating TP53 mutations occur in approximately one-third of RAS in patients without hereditary predisposition syndromes and that the inactivation of one TP53 allele represents an early event in RAS tumor formation [22]. Here, TP53 is linked to neoplasm.